On January 12, 2024, Alnylam Pharmaceuticals, Inc. and Indrani L. Franchini agreed that she would transition from her role as the Company?s Executive Vice President, Chief Legal Officer and Secretary, effective as of March 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.9 USD | -1.33% | -4.17% | -22.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.74% | 18.96B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B | |
+22.69% | 11.73B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024